Introduction
The hepatitis B virus (HBV) is a small DNA virus belonging to the Hepadnaviridae family, genus Orthohepadnavirus. In humans HBV infection results in either an acute, self-limiting disease, or a long-term infection that remains unresolved and persistent (1) . Due to complications such as end-stage liver disease and primary hepatocellular carcinoma (HCC), chronic HBV infection globally represents the leading cause of chronic liver disease and associated mortality (2) . With an estimated 257 million infected people worldwide, HBV infection presents a global public health problem despite the long-term existence of a highly effective hepatitis B prevention vaccine and relatively effective treatment of chronic hepatitis B (CHB) (3) . The prevalence of HBV infection in the general population depends on the region and ranges from 0.01% in northern European countries to 22.3% in the Pacific region (3) (4) (5) . In Europe, the average HBV prevalence has been estimated at 1.5%, with 15 million people infected (3) .
HBV has been classified into 10 different genotypes (A-J), according to the difference in overall genomic sequences (presenting more than an 8% difference) or in sequences of gene coding surface antigen (HBsAg, presenting more than a 4% difference) (6) . The prevalence of HBV genotypes varies among different parts of the world: genotype A is mainly found in northern Europe, North America, India, and Africa; genotypes B and C are most prevalent in southeast Asia; and genotype D is most prevalent in southern Europe, the Middle East, and India (7, 8) . In Europe, genotypes A and D were found to be most prevalent (9) .
HBV genotypes influence clinical outcomes of hepatitis B, clinical course, progression of the disease, chronicity, risk of HCC, mutations in the pre-core and core promoter regions, seroconversion rates of HBV e antigen (HBeAg), and response to antiviral therapy (7, 8) .
Overview and geographical distribution of HBV genotypes and subtypes
In recent years, several European and Mediterranean countries have reported on the prevalence of HBV genotypes, showing a clear geographical shift with genotype D being predominant in southeast Europe and Russia, and genotype A being most frequent in western countries and in Scandinavia (Table 1 , Fig. 1 ) . N. Kmet Lunaček et al.
Europe sporadically, with most cases being imported to Europe either as a consequence of immigration from the Middle East, Asia, and Africa in past decades, or imported by European travelers that were infected abroad. Surprisingly, recent European studies reported a prevalence of up to 41% of non-A-D genotypes in the Netherlands, 28% in France, and 26% in Switzerland (14, 21, 27) . In contrast, the genotype distribution in central European countries is still limited to genotypes A and D, and the proportion of non-A-D genotypes has not exceeded 10% (12) .
Co-infection with different HBV genotypes
Mixed genotypes are possible co-infections with two distinct HBV genotypes (32) . Sanger sequencing is the gold standard for genotype detection, but has lower sensitivity than other methods for detecting mixed genotypes because it mainly detects the predominant genotype in genotype mixtures (33, 34) . Consequently, where sequencing is routinely used, the prevalence of mixed genotypes might be underestimated. According to reports from Europe, some (35) . Some early reports have shown that a substantial fraction of chronically infected persons in central Europe, especially from the southeastern region, are infected with mixed HBV genotypes, ranging from 0.8% in Germany to 27% in Romania (9, 12) . At least some of the mixed infections detected were probably false positives due to the use of genotyping tests that lacked specificity for certain HBV genotypes.
Epidemiology of HBV genotypes in Europe
Reports from different parts of Europe show that those with sexrelated risk factors for acquiring HBV infection, especially men having sex with men (MSM), are more frequently infected with HBV genotype A. A Dutch study reported an ongoing outbreak among MSM in Amsterdam caused by a single HBV genotype A strain (36) . Similarly, in the UK, HBV genotype A is more prevalent in MSM compared to other risk groups (15) . A recent study from Slovenia also showed that MSM have been more often infected with genotype A than genotype D (26) .
A report from several central European countries suggested that, compared to genotype D, genotype A was more often found in older patients, whereas genotype D predominated in younger ones (22) . This observation might be a consequence of changing sexual and travel behaviors of the population (37), as well as the change in modes of HBV transmission. Globally, increased awareness of sexually transmitted infections (STIs) has led to more common use of prevention measures; however, the highly increased frequency of traveling, particularly to endemic areas for STIs, significantly influences the importation of STIs, including HBV infection to Europe (37) . In recent decades, due to implementation of HBsAg screening for pregnant women in many European countries, mother-to-child transmission in this part of the world has mostly been limited to children born to immigrant mothers and those with a history of family migration, particularly from the Balkan region, the Middle East, and North Africa, where genotype D prevails (10-12, 17, 19, 20, 24-26, 28-30, 38, 39) .
Epidemiological data from the literature suggest that central Europe is on its way to switching from the previously predominant genotype A to predominance of genotype D (22) . Recently, Bissinger et al. showed that in central European countries the number of observed age-related genotype A-infected persons decreased from a high level (71.4%) to average (20%), whereas in countries outside of central European only small variations in the proportion of genotype A were noticed, remaining at low rates of around 10% (22) . One of the reasons for this significant shift may be related to the ongoing global migration flow (22) due to the current geopolitical situation. Recent studies from two German regions with high proportions of immigrants from the Mediterranean area have reported genotype D infection in 40% and 58% of infected persons, respectively (12) . Similarly, Moussa et al. reported a 53% prevalence of HBV genotype D in Marseille (14) , and Hirzel reported a 58% prevalence of the same genotype in Switzerland (27) .
Clinical implications of HBV genotypes
Studies have shown that HBV genotypes influence the clinical outcome of HBV infection as well as the response to antiviral therapy (Tables 2-3) . Up until now, no systematic review or meta-analyses have been published comparing the clinical implications of all known HBV genotypes.
Studies from Asia report that the rate of spontaneous HBeAg seroconversion is higher in HBV genotype B-infected persons compared to those infected with genotype C (40) (41) (42) . In the population from Alaska, compared to those infected with genotypes A, B, D and F, HBeAg seroconversion was less commonly achieved in HBV genotype C-infected persons; genotypes C and F were associated with the highest rates of HBeAg reversion (43) .
Sánchez-Tapias et al. reported that the HBeAg seroconversion rate was quite comparable between genotype A-and D-infected persons; however spontaneous HBsAg seroconversion and biochemical remission were seen more often in persons infected with genotype A than with genotype D (44) .
Among all HBV genotypes, HBeAg-negativity was most often seen in HBV genotype D-infected persons (45, 46) . Compared to genotype A, HBeAg-negativity was more common in genotypes B and D, whereas it was found to be more common in genotype B than in genotype C (47) .
Compared to HBV genotypes C and D, genotype A is most likely to progress to chronic HBV infection (48) (49) (50) .
Studies in children showed higher HBV DNA viral loads in those infected with genotype D in comparison to those with genotype A (51). Lindh et al. showed that the viral loads in genotype D-infected HBeAg-positive patients were higher compared to the viral loads in those infected with other HBV genotypes (52) . Other studies performed in either adult or pediatric populations showed no differences in viral loads among patients infected with various HBV genotypes (26, 53, 54) . Tran et al. reported that young females of childbearing age infected with genotype D had higher viral loads compared to those infected with other HBV genotypes (55) . A similar conclusion was also drawn in our recent study in Slovenia (26) . This finding is consistent with the natural course of HBV infection (56) .
Some studies suggest that progression to cirrhosis is more common in patients infected with genotype C compared to those infected with other HBV genotypes. Genotype B-infected persons are less likely to develop liver decompensation in comparison to those infected with genotypes A, C, and D (41) . The clinical course of an infection with genotype D is more severe compared to one with genotype A (57) .
A meta-analysis performed by Wong et al. showed that, compared to other HBV genotypes, the development of HCC is most frequent in genotype C-infected persons (58) .
Up until now no randomized controlled trials on the possible influence of HBV genotypes on the fulminant course of hepatitis B have been found. However, sporadic reports suggest that, among all HBV genotypes, genotype D was found most commonly related to a fulminant course of disease (59, 60) .
A pre-core mutant of HBV does not produce HBeAg, resulting in HBeAg-negative CHB. The most frequent mutations include changes from guanine to adenine at base position 1896 (G1896A), and from cytosine to thymine at position 1858 (C1858T) in the pre-core region of the viral genome (61). Pre-core mutations are most commonly associated with HBV genotype D (65-75%) and most rarely with HBV genotype A (9-18%) (62, 63) . Pre-core mutations are found more often in genotype C-infected persons than in those infected with genotype B (64) . A national study in the United States found prevalences of pre-core mutations in HBV genotypes A, B, C and D of 3%, 46%, 24%, and 73%, respectively (47) . A meta-analysis by Funk et al. showed very high prevalences of pre-core mutations regardless of HBV genotypes in some Mediterranean countries (Italy, Greece, Turkey, Israel, Bulgaria, and Spain) ranging from 67 to 100%, whereas in Germany it ranged from 16 to 53% (65) .
A prevalence of core promoter mutations was estimated only in Germany, being 59% (65) . Basal core promoter mutants cause a reduction in HBeAg production. Mutations include changes from adenine to thymine at base position 1762 (A1762T) and from guanine to adenine at position 1764 (G1764A) in the basal core promoter region of the genome (61) . The basal core promoter region and regulatory sequences play an important role in HBV replication and HBeAg formation. A clinical consequence related to core promoter mutations is a higher prevalence of HBeAg-negative CHB, although some patients with core promoter mutations can be HBeAg-positive as well (66) . They are mostly found in genotype C-infected persons (67) . A national study from the United States found prevalences of core promoter mutations in HBV genotypes A, B, C and D of 41%, 27%, 60% and 42%, respectively (40) . Pre-S deletion is associated with faster progression of chronic disease and a higher risk of HCC, and it is more likely to be found in genotype C compared to genotype B-infected persons (68) .
Antiviral treatment and HBV genotypes
By March 2018, eight drugs had been approved for the treatment of CHB, three nucleoside analogues (lamivudine, entecavir, and telbivudin), three nucleotide analogues (adefovir, tenofovir disoproxil, and tenofovir alafenamide), and standard/pegylated interferon alpha (IF; PegIFN) (69) . The aims of antiviral treatment are suppression of HBV replication, permanent suppression of the viral load, seroconversion of HBeAg and HBV surface antigen (HBsAg), normalization of aminotransferase levels, and a decrease in inflammation and fibrosis of the liver. Treatment has also been proven to prevent progression to cirrhosis and HCC (69) . In 2017 the European Association for the Study of the Liver (EASL) published updated recommendations for CHB management and treatment mostly based on recent findings (69) .
While a meta-analysis published in 2008 presented no difference in the nucleoside/nucleotide (NUC) treatment response among different HBV genotypes (70) , other studies showed that response rates to treatment with PegIFN differ by HBV genotype and by HBeAg-status (71) (72) (73) (74) (75) (76) (77) .
In HBeAg-positive CHB patients, pretreatment predictors of treatment response success are low HBV DNA viral load, high serum ALT levels (above two to five times the upper limit normal, ULN), HBV genotype, and high activity scores on liver biopsy. Genotypes A and B have been shown to be associated with higher rates of HBeAg seroconversion and HBsAg loss than genotypes C and D. In HBeAg-negative CHB patients, high baseline ALT, low baseline viral load, younger age, female sex, and HBV genotype were independent predictors of response to PegIFN therapy. Patients with genotypes B or C have a better chance of response than genotype D patients (69) .
According to the latest EASL guidelines, PegIFN can be considered as an initial treatment option for patients with either HBeAg-positive or HBeAg-negative chronic infection. At week 12 of PegIFN treatment in HBeAg-positive CHB, HBsAg levels above 20,000 IU/ml for genotypes B and C, or persistent HBsAg levels for genotypes A and D, are associated with a low HBeAg seroconversion rate, suggesting therapy should be stopped. HBsAg above 20,000 IU/ml persisting at week 24 in genotype A-D mean a low probability of HBeAg seroconversion, recommending stopping treatment as well. In HBeAg-negative persons infected with genotype D, a combination of no decrease in HBsAg levels and less than log10 IU/ml reduction in viral load at week 12 predicts no response to the therapy, which should be stopped (69).
Janssen et al. reported up to a 47% response rate to PegIFN in HBeAg-positive genotype A-infected patients and 25% in genotype D-infected patients (71). Buster et al. suggest the use of PegIFN in all genotype A HBeAg-positive patients and in genotype B and C patients presenting with high ALT levels and low viral load (72) . Response rates to PegINF in patients infected with genotypes E, F, G, and H have been shown to be poor (73, 74) . A Taiwanese study showed that more patients infected with genotype B lost HBeAg after PegIFN treatment than those infected with genotype C (75) . Regardless of the HBeAg-status, the response rate to PegIFN therapy has been highest in genotype A (76), as well as leading to more stable remission (77) .
Conclusions
Infection with a particular HBV genotype has several practical implications because it may influence the clinical outcome of the disease, as well as the outcome of antiviral treatment. A recent shift in the distribution of particular HBV genotypes in certain European countries as a consequence of large-scale migration flows and travel-related sexual transmissions may influence the choice of HBV treatment. Because the choice of antiviral drugs also depends on the HBV genotype, HBV genotyping before the introduction of antiviral treatment might be introduced for selected patient populations-for example, migrants and men with a history of high-risk sexual behavior. In Europe, studies have shown a predominance of genotype A in MSM in particular, in contrast to the general population, enabling treatment with PegIFN instead of NUCs.
